In our experience, the Kumamoto scale is a good and validated tool for clinical follow-up of ATTRv amyloidosis that should be combined with a detailed medical history, a general physical examination, biomarkers (albumin, creatinine, troponin T or I and nt-proBNP), nutritional status (modified body mass index, mBMI), and some functional status scales like the Karnofsky performance scale, the New York Heart Association (NYHA) scale, and the Polyneuropathy Disability (PND) scale to compensate for its limitations. The gene discussed is ALB; the disease is amyloidosis.